---
title: "Aethlon Medical reports biomarker shifts in second cohort of Hemopurifier cancer trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292485775.md"
description: "Aethlon Medical reported similar biomarker shifts in the second cohort of its Hemopurifier cancer trial for advanced solid tumors. Observed reductions in tumor-related extracellular vesicles, including PD-L1-positive vesicles, alongside increased T-cell measures persisting through eight weeks. Enrollment continues in the final cohort, with independent statistical analysis planned upon completion to assess dose-response signals. Results remain preliminary as the study is not designed to demonstrate clinical efficacy."
datetime: "2026-07-13T12:06:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292485775.md)
  - [en](https://longbridge.com/en/news/292485775.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292485775.md)
generator: "portal-rs"
---

# Aethlon Medical reports biomarker shifts in second cohort of Hemopurifier cancer trial

-   Aethlon Medical reported similar biomarker shifts in cohort 2 of its Australian oncology feasibility study of Hemopurifier in advanced solid tumors. \* Observed reductions in tumor-related extracellular vesicles, including PD-L1-positive vesicles, with increases in T-cell measures that generally persisted through eight weeks. \* Enrollment continues in the third and final cohort; an independent statistical analysis is planned once all cohorts are completed to assess a dose-response signal. \* Results remain preliminary; the study is not designed to show clinical efficacy or patient-outcome benefit. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA02512) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [AEMD.US](https://longbridge.com/en/quote/AEMD.US.md)

## Related News & Research

- [Aethlon Medical: Pre-Revenue Status, Ongoing Cash Burn, and Early Hemopurifier Progress Support Balanced Risk/Reward and Hold Rating](https://longbridge.com/en/news/296262387.md)
- [Aethlon Medical (AEMD) Fiscal Q1 2027 Earnings Call: Oncology Trial Enters Final Cohort](https://longbridge.com/en/news/295899977.md)
- [Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) Builds Foundation for Biomarker-Driven Cancer Therapy](https://longbridge.com/en/news/296130343.md)
- [BioInvent says BI-1808 posts promising activity in ongoing Phase 2a cancer trials](https://longbridge.com/en/news/296486934.md)
- [Why Iovance Biotherapeutics Stock Hit 52-Week High](https://longbridge.com/en/news/296522969.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**